CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today their participation in two October conferences, the 2022 Cell & Gene Meeting on the Mesa on October 11-13, 2022 and the 14th World Stroke Congress on October 26-29, 2022.
Dr. Robert W. Mays, Executive Vice President and Head of Regenerative Medicine & Neuroscience, will present live at the 2022 Cell & Gene Meeting on the Mesa in Carlsbad, California on October 11. Dr. Mays will provide a corporate overview of the Company’s therapeutic MultiStem® cellular therapy, and an update on preclinical and clinical perspectives utilizing the MultiStem cellular platform technology to date. The presentation will provide an overview of the Company’s ongoing clinical studies in ischemic stroke, acute respiratory distress syndrome and trauma. Mr. Dan Camardo, Chief Executive Officer, Ms. Maia Hansen, Chief Operating Officer, and Dr. Sarah Busch, Vice President of Regenerative Medicine and Head of Non-Clinical Development, will also be in attendance from October 11-13 to meet with registered attendees.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference that brings together senior executives and top decision-makers in the industry to highlight technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering and broader regenerative medicine technologies.
The following are specific details regarding the Athersys presentation at the Cell & Gene Meeting on the Mesa conference:
Event: |
The 2022 Cell & Gene Meeting on the Mesa |
Date: |
Tuesday, October 11, 2022 |
Time: |
4:00 PM Pacific Time |
Location: |
Oxford Biomedica Ballroom, Park Hyatt Aviara Resort, Carlsbad, CA |
A live video webcast of all company presentations and sessions will be available for registered participants and will also be published on the conference website after the event concludes. In addition, a webcast of the corporate presentation by Dr. Mays will be posted on the investor section of www.athersys.com when it becomes available. Please visit www.meetingonthemesa.com for detailed conference information and registration.
Additionally, Dr. Mays will be attending the 14th World Stroke Congress on October 26-29 to meet virtually with global professionals and stroke specialists to discuss the latest science, clinical trials, breakthroughs, and guidelines to stroke prevention. The hybrid Congress is organized by the World Stroke Organization, whose mission is to reduce the global burden of stroke through prevention, treatment and long-term care. Please visit https://worldstrokecongress.org/ for additional information and registration.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com and on our social media accounts. Follow Athersys on Twitter at www.twitter.com/athersys. Information that we may post about the Company on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
About MultiStem
MultiStem (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique "off-the-shelf" stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, statements regarding the potential benefits of our MultiStem product candidate; anticipated results of clinical trials involving our MultiStem product candidate; the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: the possibility of unfavorable results from ongoing and additional clinical trials involving MultiStem; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in an early stage clinical trial may not be predictive of results in later stage or large scale clinical trials; our ability to raise capital to fund our operations in the near term, including, but not limited to, our ability to raise financing and to continue as a going concern; our ability to enter into a partnership for the co-development and co-commercialization of MultiStem; our ability to successfully implement our transformation plan, including our ability to reduce expenses; and the risks mentioned elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2021 under Item 1A, “Risk Factors” and our other filings with the SEC. You should not place undue reliance on forward-looking statements, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
